

Are you living with Progressive Pulmonary Fibrosis (PPF)?

NOW ENROLLING:

mist
A PPF CLINICAL STUDY



About the MIST Study

Progressive Pulmonary Fibrosis (PPF) is a rare lung disease that causes lung scarring. This makes it hard to breathe.

This is a Phase 2b study, or clinical trial. The goal of the MIST Study is to learn more about the investigational study medicine: an inhaled version of pirfenidone called AP01.

Why join the study?

There is no cure for PPF. Current treatments in pill form can slow the disease in some people. However, high doses are needed for the swallowed medicine to reach the lungs, which may cause side effects.

Researchers want to know if an inhaled form of pirfenidone (AP01) may improve lung function and have fewer side effects.

New treatments are developed through clinical research studies. By volunteering to join a study, you can help researchers learn more about PPF.

Who can join the study?

- Adults ages 18 and over diagnosed with PPF (not idiopathic pulmonary fibrosis)
- Meets spirometry test requirements
- Meets other study requirements shared by the study doctors

What to expect



12 months long (or more, for participants who choose to continue on an extension study)



The study medicine or a placebo will be inhaled by nebulizer twice a day



Medical exams and tests at most appointments



Study exams, tests and treatments, provided at **no charge** to participants



Frequent appointments with study doctors



Many study sites across the U.S.

Learn more:



Talk to your doctor to find out if the MIST Study is an option for you



MISTPPFStudy@avalynpharma.com



[MISTPPFStudy.com](https://www.MISTPPFStudy.com)

[ClinicalTrials.gov](https://www.ClinicalTrials.gov) (search for NCT#06329401)

Study sponsor:

Avalyn Pharma is a biopharma company focused on developing medicines for rare lung diseases.



AP01 is an investigational drug-device combination and is not approved by any health authority.